LANIER ET AL . BRIEF DEFINITIVE REPORT
Tris-maleate buffer (20 mM Tris-maleate, 10 MM D-galactono-, y-lactone, 1 mM calcium acetate, 0.5% NP-40, 0.02 mg/ml trypsin inhibitor, 1 mM PMSF, pH 6.0) for 4 h at 37'C . Digestion with Endo F was performed as recommended by New England Nuclear (Boston, MA).
Peptide mapping was performed as described by Cleveland et al. (10) , using protease type XVII from Staphylococcus aureus strain V8 (Sigma Chemical Co.).
Results and Discussion N-CAM is a membrane glycoprotein expressed on neural and muscle tissues that is involved in homotypic adhesive interactions . Recently, we have observed that Leu-19 (CD56) is present on human neural tissues and neural-derived cell lines. In spinal cord, Leu-19 was strongly expressed throughout the gray and white matter. Cell surface staining was particularly prominent on the radiating glial septae of the white matter. In brain, Leu-19 was widely expressed throughout the molecular and granular layers of the cerebellum, as well as the cortex . These findings were consistent with the distribution of N-CAM on neural tissues and suggested that Leu-19 may be similar to N-CAM.
The presence of Leu-19 on neural tissues prompted us to examine whether it is related to N-CAM . KGla.5, an immature hematopoietic cell line, and SK-N-SH, a neuroblastoma cell line, were labeled with "'I and detergent solubilized. Antigens were immunoprecipitated using anti-Leu-19 mAb and rabbit anti-N-CAM serum. Samples were treated with neuraminidase and analyzed by SDS-PAGE . Anti-Leu-19 and anti-N-CAM immunoprecipitated a predominant band of -145 kD from both the hematopoietic and neuroblastoma cells (Fig. 1 A) . Mobility of Leu-19 was essentially identical when analyzed using both reducing ( Fig. 1 ) and nonreducing conditions (not shown) . Sequential immunoprecipitation confirmed that anti-Leu-19 and anti-N-CAM reacted with the same molecule (Fig. 1 B) . Moreover, peptide mapping using S aurew V8 protease indicated that the Leu-19 glycoproteins expressed on the hematopoietic and neuroblastoma cells were indistinguishable (Fig. 2) . These results clearly demonstrate that anti-Leu-19 mAb reacts with the N-CAM molecule, and that the structure expressed on hematopoietic cells is similar to the form present on a neural cell line . Northern blot analysis revealed N-CAM transcripts in both KGla.5 and NK cell lines (S. Cwirla and L. Lanier, unpublished observation) .
Although N-CAM is encoded by a single gene, several isoforms can be generated by alternative splicing and differential polyadenylation (3, 5) . Polypeptides of 180, 140, and 120 kD have been isolated from neural tissue, and 155-, 145-, and 125-kD proteins are present in muscle tissue (1, 2) . The smaller forms (120 and 125 kD) are anchored to the cell membrane via a phosphatidylinositol glycan linkage, whereas the larger forms possess a transmembrane peptide segment (5). Additional diversity in N-CAM structure can be conferred by glycosylation, phosphorylation, sulphation, and sialyation (1, 2) .
In hematopoietic tissues, Leu-19 is expressed on several cell types, including NK cells, T lymphocytes, and some myeloid leukemias (6) (7) (8) . Since N-CAM can be expressed as several structural isoforms, further studies were conducted to compare the biochemical properties of Leu-19 expressed on hematopoietic cell types. Leu-19 immunoprecipitates prepared from ' 21 1-labeled lysates of NK cells, Leu 19+ T cells, and KGla.5 were treated with Endo F to remove N-linked carbohydrates and analyzed by SDS-PAGE . Deglycosylated Leu-19 expressed by NK cells and Leu-19+ T lymphocytes is a 137-kD protein, similar to the polypeptide expressed on KGla.5 (Fig. 3) . Note that before deglycosylation, the mobility ofLeu-19 isolated from normal T and NK cells was similar to the mobility of Leu-19 on KG1a.5, indicating that the extent of sialyation is similar in these cell types.
Further biochemical analysis of Leu-19 expressed on hematopoietic cells indicated that the glycoprotein was resistant to cleavage by Endo H and 0-glycanase, enzymes that remove high mannose and 0-linked carbohydrates, respectively (not shown) . Therefore, it appears that the carbohydrates present on Leu-19 on hematopoietic cells are exclusively complex N-linked oligosaccharides with abundant sialyation . Leu-19 on hematopoietic cells was resistant to removal by phosphatidylinositol phospholipase C (PIPLC) (not shown) . Given the size of the polypeptide (140 kD) and the inability to cleave Leu-19 using PIPLC, the molecule is likely anchored to the membrane via a transmembrane peptide.
An unusual structural feature of N-CAM is the abundance of sialic acid on this molecule (3) . The extent of sialyation changes during embryonic development and can influence N-CAM binding function (11) . We have shown that the epitope recog-FIGURE 2. Peptide mapping of Leu-19. Leu-19 bands were cut from the SK-N-SH neuroblastoma (Nb) and KGla.5 (K) lanes shown in Fig. 1 , digested for 1 h with 0, 5, and 25 jig of S aurtus V8 protease, and analyzed by SDS-PAGE (reducing conditions) using a 15 % acrylamide gel.
nized by anti-Leu-19 mAb is not dependent on sialic acid, since treatment of viable cells with neuraminidase did not diminish the binding of anti-Leu-19 as determined by flow cytometry (not shown) . In fact, neuraminidase treatment increased binding of anti-Leu-19, indicating that Leu-19 epitopes are partially masked by sialic acid . We have observed that the amount of Leu-19 increases on NK cells after activation with IL-2 (unpublished observation), and that subsets of NK cells can be identified based on relative density of Leu-19 expression (6) . It will be interesting to determine whether this increase in Leu-19 is a result of de novo protein synthesis or alteration in sialyation. As in neural cells, sialyation may affect the function of Leu-19 on leukocytes .
In normal lymphoid tissues, Leu-19 is expressed predominantly on NK cells and a subset of T lymphocytes that mediate MHC-unrestricted cytotoxicity (6) (7) (8) . Although this preferential distribution suggests that Leu-19 may be important in cytotoxicity, the function ofLeu-19 on these cells has not been determined. Anti-Leu-19 mAb does not inhibit cytotoxic activity of NK or T cells against several tumor cell targets and does not affect IL-2-induced cellular proliferation (6) (7) (8) . However, negative results from antibody blocking studies are inconclusive . Given the role of N-CAM in neural cell adhesion, it is conceivable that Leu-19 also may be involved in lymphocyte adhesion . Further studies will be necessary to examine this possibility.
Summary
Neural cell adhesion molecule (N-CAM) is a membrane glycoprotein expressed on neural and muscle tissues that is involved in homotypic adhesive interactions. We have demonstrated that N-CAM also is expressed on hematopoietic cells, and is recognized by the anti-Leu-19 mAb. Leu-19 is preferentially expressed on NK cells and T lymphocytes that mediate MHC-unrestricted cytotoxicity, but is also present on some myeloid leukemia cell lines. On NK cells, T cells, the KGla.5 hematopoietic cell line, and a neuroblastoma cell line, Leu-19 is a ti 140-kD polypeptide with N-linked carbohydrates and abundant sialic acid residues. Sequential immunoprecipitation and peptide mapping demonstrated that the Leu-19 and N-CAM molecules expressed on leukocyte and neuroblastoma cell lines are similar structures . These findings suggest that the Leu-19 antigen on leukocytes may be involved in cell adhesion, analogous to the function of N-CAM on neural cells.
